Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Trinity Biotech (TRIB) EBT Margin (2016 - 2024)

Trinity Biotech's EBT Margin history spans 16 years, with the latest figure at 99.62% for Q4 2024.

  • On a quarterly basis, EBT Margin fell 5863.0% to 99.62% in Q4 2024 year-over-year; TTM through Dec 2024 was 49.92%, a 1506.0% increase, with the full-year FY2025 number at 84.91%, down 3499.0% from a year prior.
  • EBT Margin hit 99.62% in Q4 2024 for Trinity Biotech, down from 31.64% in the prior quarter.
  • Over the last five years, EBT Margin for TRIB hit a ceiling of 32.17% in Q3 2020 and a floor of 133.93% in Q2 2023.
  • Historically, EBT Margin has averaged 31.97% across 5 years, with a median of 36.32% in 2024.
  • Biggest five-year swings in EBT Margin: tumbled -10109bps in 2022 and later soared 9045bps in 2024.
  • Tracing TRIB's EBT Margin over 5 years: stood at 31.41% in 2020, then crashed by -140bps to 12.44% in 2021, then plummeted by -433bps to 66.32% in 2022, then surged by 38bps to 41.0% in 2023, then plummeted by -143bps to 99.62% in 2024.
  • Business Quant data shows EBT Margin for TRIB at 99.62% in Q4 2024, 31.64% in Q3 2024, and 43.48% in Q2 2024.